Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Streamlined Brain and Skull Modeling for Enhanced Neurosurgical Planning in NHP Research
Published on: February 9, 2024
Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates
Sean P Brown1, Paul Dransfield1, Marc Vimolratana1
1Department of Medicinal Chemistry, Amgen Discovery Research, One Amgen Center Drive, Thousand Oaks, California 91320, United States.
Abstract:
GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets and enteroendocrine L-cells, and, when activated, elicits increased insulin secretion only in the presence of elevated glucose levels. We recently reported the discovery of AM-1638 (2), a full agonist of GPR40. Herein, we present further structure-activity relationships progressing from AM-1638 (2) to AM-6226 (14) that possesses a profile acceptable for dosing cynomolgus monkeys. The GPR40 full agonist AM-6226 (14) is the first molecule to display significant glucose lowering in cynomolgus monkeys providing additional evidence that GPR40 full agonists afford access to a powerful mechanism for maintaining glycemic control.
Related Concept Videos
Bioavailability: Overview
Bioavailability: Overview
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Self-Efficacy
Drug Discovery: Overview

